Today: 4 June 2026
Google stock price: Alphabet (GOOG) in focus after Waymo school-bus probe, with Fed week ahead
25 January 2026
2 mins read

Google stock price: Alphabet (GOOG) in focus after Waymo school-bus probe, with Fed week ahead

New York, January 25, 2026, 09:32 EST — Market closed.

  • Alphabet Class C shares (GOOG) closed Friday down 0.73%, finishing at $328.43.
  • U.S. investigators launched a safety probe into Waymo, Alphabet’s self-driving unit, after reports that its robotaxis passed stopped school buses in Texas.

Alphabet’s Class C shares enter Monday’s U.S. session amid new regulatory scrutiny of Waymo. The U.S. National Transportation Safety Board has launched an investigation into the robotaxi operator after reports that Waymo vehicles passed stopped school buses illegally in Austin at least 19 times. This occurred despite a software update connected to a recall affecting more than 3,000 vehicles. Waymo maintains it is “confident” its safety record around school buses surpasses that of human drivers. Reuters

GOOG slipped 0.73% to $328.43 on Friday, falling behind a handful of other megacap giants amid a patchy market. About 19 million shares changed hands.

Timing is key. This week, regulators, central bankers, and earnings reports are all poised to shake the tape, and Alphabet’s stock usually feels those shifts in risk appetite.

Waymo doesn’t headline Alphabet’s earnings report, yet it remains one of the company’s most high-profile long-term bets. Increased safety scrutiny could slow deployment, push up compliance expenses, or force Alphabet to limit operations in certain regions.

U.S. stocks wrapped up Friday with the Nasdaq climbing 0.3%, while the Dow slipped roughly 0.6%. It was a choppy week, driven by earnings reports and changing bets on interest rates.

All eyes turn to rate expectations once more. The Federal Open Market Committee, the Fed’s rate-setting panel, is scheduled to meet January 27-28. Their statement and Chair Jerome Powell’s press briefing will follow on January 28.

There’s a shift in some key macro data releases. The Bureau of Economic Analysis pushed back the advance GDP estimate for Q4 from January 29 to February 20. On that same day, they’ll also release December personal income and outlays.

Tech’s next big catalyst: earnings. Microsoft will report after the bell on January 28, followed by its earnings call at 2:30 p.m. Pacific time.

Meta Platforms will report earnings after the close on January 28. The company’s conference call is set for 4:30 p.m. Eastern time.

Apple is set to release its first-quarter earnings on Thursday, January 29. The report will offer fresh insight into consumer demand and how its services segment is performing—data that often ripples through the wider big-tech landscape.

Alphabet is set to release its fourth-quarter and full-year 2025 earnings on February 4. The company will hold a conference call at 1:30 p.m. Pacific time (4:30 p.m. Eastern).

Near-term, the headline loop poses the biggest risk. Should the Waymo probe expand or regulators clamp down with stricter operating rules, uncertainty will spike right as the market grapples with Fed signals and a heavy schedule of megacap earnings. Investors will focus on Monday’s open for the initial cues, then on the Fed meeting January 28, followed by Alphabet’s earnings on February 4.

Stock Market Today

  • LanzaTech JV Raises $75 Million in Hong Kong IPO, Shares Surge
    June 4, 2026, 2:26 PM EDT. LanzaTech Global's joint venture Beijing Shougang LanzaTech raised about $75 million through an initial public offering on the Hong Kong Stock Exchange. The company sold 40 million H-shares at roughly $1.86 per share, valuing the venture near $750 million. LanzaTech's stake adjusted to 8.38% post-IPO. The venture operates four commercial plants using LanzaTech's carbon recycling technology, reporting revenue between $77 million and $87 million from 2023 to 2025. Nasdaq-listed LanzaTech shares jumped over 26% to $6.90 following the listing, reflecting strong investor interest in sustainable fuel solutions.

Latest articles

Grab Stock Bounces While Nasdaq Sags—What Traders Are Waiting For Next

Grab Stock Bounces While Nasdaq Sags—What Traders Are Waiting For Next

4 June 2026
Grab Holdings’ U.S. shares jumped 2.9% to $3.51 as investors weighed strong Q1 results—revenue up 24% to $955 million, adjusted EBITDA up 46% to $154 million—and the consolidation of Indonesia’s Superbank, now majority-owned by Grab, against risks from higher fuel costs and regional regulation, leaving the stock sensitive to further updates on profitability and fintech growth.
Goldman Sachs Jumps as Dow Sets New High

Goldman Sachs Jumps as Dow Sets New High

4 June 2026
Goldman Sachs shares surged 4.6% to $1,095.89, powering the Dow to an all-time high as investors rotated into financials; the move was amplified by Goldman’s high share price in the price-weighted Dow, while the bank’s lead role in the $75 billion SpaceX IPO and strong Q1 earnings added momentum, even as analysts flagged risks from high IPO valuations and geopolitical uncertainty.
Celsius Drops in New York After Texas Inquiry Hits Alani Nu Play

Celsius Drops in New York After Texas Inquiry Hits Alani Nu Play

4 June 2026
Celsius shares plunged 6.8% to near a 52-week low after Texas opened a probe into whether its Alani Nu drinks misled consumers about safety for minors, raising fresh legal and consumer-safety concerns just as the company relies on Alani Nu for growth and integration with PepsiCo’s distribution system.
Veru shares jump after Novo Nordisk deal draws traders

Veru shares jump after Novo Nordisk deal draws traders

4 June 2026
Veru shares soared 112% to $4.78 after announcing Novo Nordisk will supply Wegovy at no charge for Veru’s Phase 2b obesity trial, with Veru retaining global rights to enobosarm but granting Novo a right of first negotiation; analysts called the deal a “significant event” and kept $24–$25 targets, while Veru warned trial risks and reimbursement challenges remain.
CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics Jumps 12% in New York Trading

4 June 2026
CRISPR Therapeutics shares soared 11.7% to $58.15 after presenting at the Jefferies Global Healthcare Conference, with sector momentum lifting gene-editing stocks and the SPDR S&P Biotech ETF up 3.0%. Casgevy, its key sickle cell therapy, posted $43 million Q1 revenue, but a $122.9 million net loss and biotech risks mean the rally hinges on investor appetite and upcoming clinical updates.
Hycroft Mining stock price jumps on $100 silver surge — what HYMC investors watch next
Previous Story

Hycroft Mining stock price jumps on $100 silver surge — what HYMC investors watch next

TSMC stock price ends week higher — what to watch before the next session
Next Story

TSMC stock price ends week higher — what to watch before the next session

Go toTop